Knowledge Hub
Information you can trust.
Free, evidence-based resources for patients, families and health professionals navigating neuroendocrine cancer in Aotearoa New Zealand. Written in plain language, reviewed by clinicians.
48 resources
Page 2 of 2
Understanding NET cancer15 Sept 2024NETTER-2 supports PRRT as a first-line option in advanced GEP-NETs
The Phase 3 NETTER-2 trial showed Lutathera plus octreotide nearly tripled progression-free survival when used as first-line therapy in grade 2/3 GEP-NETs.
Read
News15 Aug 2024In memory of Associate Professor Dr Malcolm Legget














